Pharmacogenomics: an Assessment of Market Conditions and Competition

Print

Download: 

HCFOfindings_pharmacogenomics.pdf

How can pharmacogenomics (PGx) be introduced into the current health care market? Louis F. Rossiter, Ph.D., examined the current market system to determine whether PGx could flourish in the current financing, delivery, and payment environment and found that the current U.S. payment system is not designed for PGx and therefore inadequate for PGx products and services to meet their maximum treatment potential. Learn more in the HCFO Findings Brief.